Hua Medicine Gets $50M
San Francisco- and Shanghai-based Hua Medicine, a developer of treatments for diabetes, says it has raised $50M in a Series C financing. The funding was led by Harvest Investments, and also included Frontline BioVentures, ARCH, Venrock, Fidelity, WuXi Ventures, SAIl, ALly Bridge Group, and TF Capital. The company said it was advised by China Renaissance in the funding. Hua Medicine is led by CEO Li Chen.
posted on Monday, April 25, 2016
Related companies:
Hua Hong Group
Related stories:
> Medpedia Creates Online Medical Encyclopedia
> Omicia Finds $23M For Precision Medicine
> Second Genome Digests Series A
> SV Life Sciences Promotes Guyer
> Reliant Technologies Raises $15M
silicontap.com Home